Novartis' new adaptation to strong and straight spina blinitis has been approved by the NMPA

On April 28th, Novartis Pharmaceuticals (China) announced that kosin (Scucciyu mono-resistance) had been approved by the State Drug Administration to treat adult patients with mandatory spina brysanthemum, which is currently the first and only white-media inhibitor approved for the treatment of mandatory spina boutitis.THE results of MEASURE 2 show that good health can quickly relieve back pain, morning stiffness and fatigue symptoms, and can inhibit new bone formation and prevent structural damage. Patients were randomly treated with 150 mg of sage or placebo until week 4, with back pain improving by 39% over baseline in the treatment group compared to 15% in the placebo group, morning stiffness in the treatment group improving by 34.4% over baseline, and fatigue in the treatment group by 28% compared to baseline, compared with 8% in the placebo group. Clinical results showed that after good treatment, 80% of patients within 2 years without new bone weight, nearly 80% of patients spinal injury within 4 years did not appear to worsen. The results showed good overall safety and tolerance, and there were no reports of increased susceptivity of tuberculosis in patients treated with good treatment, no reports of hepatitis B reactivation, and the incidence of drug-resistant antibodies in 5 years was less than 1%.Strong spina blinitis is a chronic inflammation that occurs in the patient's spine , the course of the disease is long, after the deterioration of the patient will lose most of the ability to move. Susceptible genes and family history are the main cause of strong spina blinitis, so the number of patients with strong spina blinitis in China is relatively stable. From 2014 to 2018, the number of people with severe spina blingitis in China increased from 3.76 million to 3.850 million, with a compound annual growth rate of 0.6%, according to frostshavin. It is expected that the number of patients with severe spina boutitis in China will reach 3.955 million by 2023, with a compound annual growth rate of 0.5%, and the number of subsequent patients will continue to grow at a compound annual growth rate of 0.4%, reaching 4.054 million by 2030.Secukinumab (commodity name: Cosentyx/ Can be good, commonly known as "Sukin monoanti" ) is Novarma developed a target IL-17A all-human source IgG1 monoclonal antibody It was approved by the FDA in 2015 and is currently available in more than 80 countries and territories, including EU countries and the United States, with adaptations including psoriasis arthritis (PsA), plaque psoriasis (PsO), and strong straight spina blinitis (AS).

-17A is the core pathogenic factor involved in psoriasis, joint disease psoriasis and inflammation of myodyngitis and disease progression. IL-17A can be produced by il-23 dependence and IL-23 non-dependent two ways, by the innitive immune system and adaptive immune system of a variety of cells. By acting directly on IL-17A from different sources, Scucciyu monoantigen has demonstrated long-lasting efficacy and safety in all areas of psoriasis, including A, scalp, palm and joints.Skuchiyu monoantigen is one of the first clinically urgent overseas new drugs in China and was approved by NMPA in March 2019 to treat moderate to severe plaque-like psoriasis in adult patients with systemic treatment or phototherapy signs, and was officially listed in China in May of the same year. The new allergy to severe spina blinitis (acceptance number: JXSS1900025) was declared public in May 2019 and was approved as a priority in August.The outstanding performance in the field of psoriasis and severe spina boutitis has made Scudchyu monoantigen the best-selling drug of 2019, with global sales reaching US$3.55 billion in 2019, up 25% year-on-year.
(
Sina Medical News)